Pregnenolone Research Overview (also known as Preg, Pregnenolone sulfate, 3beta-Hydroxypregn-5-en-20-one, Delta-5-Pregnenolone, Arthenol)
Pregnenolone is the master precursor neurosteroid synthesized from cholesterol in the mitochondria of steroidogenic tissues including the adrenals, gonads, and brain, serving as the biochemical starting point for virtually all steroid hormones including DHEA, progesterone, cortisol, testosterone, and estrogens. As a neurosteroid, pregnenolone itself exerts direct effects on cognitive function, memory consolidation, mood regulation, and neuroprotection by modulating GABA-A, NMDA, and sigma receptors in the central nervous system. Research demonstrates age-related decline in both peripheral and brain pregnenolone levels, with supplementation research exploring benefits for memory, schizophrenia, bipolar disorder, PTSD, and neuroinflammation.
What Is Pregnenolone?
Pregnenolone is a naturally occurring steroid synthesized from cholesterol and is often described as the upstream or "master" precursor of steroidogenesis. In steroid-producing cells, cholesterol is transported into the mitochondrial inner membrane by the steroidogenic acute regulatory protein, commonly abbreviated StAR. There, the cholesterol side-chain-cleavage enzyme CYP11A1, also called P450scc, converts cholesterol into pregnenolone. This first reaction initiates several interconnected pathways that produce progesterone, dehydroepiandrosterone (DHEA), androstenedione, testosterone, estrogens, cortisol, aldosterone, and other steroid hormones. The direction and amount of conversion depend on tissue-specific enzymes, cellular signals, sex, age, metabolic state, and endocrine feedback. Pregnenolone is therefore not simply a reservoir that is uniformly converted into every downstream hormone; it is a branching intermediate whose fate differs among the adrenal cortex, gonads, placenta, peripheral tissues, and nervous system.
Pregnenolone also has a second identity as a neurosteroid. Steroids made within the brain, or synthesized there from circulating precursors, can act rapidly on neuronal receptors independently of classical genomic hormone signaling. Pregnenolone and its sulfated metabolite, pregnenolone sulfate, have been investigated for effects on memory, excitability, synaptic plasticity, stress responses, and neuroprotection. Brain steroidogenesis was recognized as biologically important through work showing that some steroids are present in the nervous system even when peripheral endocrine sources are limited, and that neural tissue contains steroidogenic enzymes. Pregnenolone sulfate has a receptor profile that differs from unconjugated pregnenolone and is more strongly associated in experimental systems with modulation of NMDA, GABA-A, nicotinic acetylcholine, sigma, and other signaling systems. Circulating DHEA and some neurosteroid measures generally decline with age, prompting the hypothesis that reduced steroidogenic capacity may contribute to an age-related state sometimes called "steroidogenic insufficiency." This concept remains a research model rather than a universally accepted clinical diagnosis, and low pregnenolone alone does not establish that supplementation is appropriate.
Research Indications
Schizophrenia Adjunct Research
Negative and cognitive symptoms
Randomized adjunctive trials have evaluated oral pregnenolone alongside stable antipsychotic treatment, with some studies reporting improvement in selected negative, cognitive, or anxiety-related symptom measures.
Adjunct rather than replacement therapy
Clinical research has used pregnenolone as an add-on to prescribed treatment; evidence does not support substituting it for antipsychotic medication or psychiatric care.
Mood and Trauma-Related Disorders
Post-traumatic stress disorder
Small controlled studies in veterans have investigated pregnenolone as an adjunct for chronic PTSD symptoms. Larger confirmatory studies are needed.
Bipolar depression
Pilot clinical work has explored pregnenolone for depressive symptoms in bipolar disorder, but findings remain insufficient for routine clinical use.
Neurosteroid Biology
GABAergic and glutamatergic signaling
Pregnenolone and its downstream neurosteroids have been studied for effects on neurotransmitter systems, including GABA-A and NMDA receptor-related pathways.
Steroid precursor role
Pregnenolone is a precursor to progesterone, DHEA, corticosteroids, estrogens, and androgens; conversion patterns vary substantially among individuals and tissues.
Cognition and Healthy Aging
Age-associated cognitive complaints
Despite common supplement marketing claims, controlled evidence for improved cognition or anti-aging effects in healthy adults is limited and inconclusive.
Endocrine assessment context
Low measured pregnenolone alone does not establish a treatment indication; interpretation of steroid testing should be performed by a qualified clinician in clinical context.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Low-dose exploratory supplementation | 5–25 mg | Once daily | Oral |
| Mood or stress-related pilot research | 25–100 mg | Once daily | Oral |
| Schizophrenia adjunct trials | 30–500 mg | Once daily | Oral |
| PTSD clinical research | 100–500 mg | Once daily | Oral |
Timing
Research protocols generally administer pregnenolone once daily, often in the morning. Taking it with food may improve tolerability for some individuals. Because it is a steroid precursor, changes should be made gradually and monitored with a clinician when hormonal symptoms or concurrent hormone therapy are relevant.
Peptide Interactions
Both participate in steroid-hormone pathways; combined use may increase unpredictable androgenic, estrogenic, or mood-related effects.
Pregnenolone can convert to progesterone; concurrent therapy may complicate interpretation of hormonal effects and adverse symptoms.
Use with oral contraceptives or menopausal hormone therapy should be clinician-reviewed because pregnenolone may alter the broader steroid-hormone environment.
Combined exposure may increase acne, hair changes, irritability, libido changes, or other androgen-sensitive effects in susceptible individuals.
Individuals using prednisone, hydrocortisone, or other corticosteroids should seek medical advice, particularly when adrenal or endocrine disease is present.
Clinical trials used pregnenolone with stable antipsychotic regimens under supervision; self-directed changes in psychiatric medication or supplement use can destabilize symptoms.
Reported Research Timeline
01Days 1–7 (reported in cited studies): some individuals report changes in sleep, energy, dream vividness, mood, or gastrointestinal comfort; others notice no immediate subjective effect.
02Weeks 1–2 (reported in cited studies): early intolerance, if it occurs, may include restlessness, headache, insomnia, irritability, acne, or changes in libido.
03Weeks 3–4 (reported in cited studies): in research settings, symptom measures are typically reassessed after sustained daily exposure rather than judged from day-to-day fluctuations.
04Weeks 4–8 (reported in cited studies): controlled psychiatric studies commonly evaluate outcomes over several weeks; meaningful benefit is not established for healthy cognitive enhancement.
05Weeks 8–12 (reported in cited studies): continued use warrants review of benefit, adverse effects, concurrent medications, and possible hormone-related symptoms with a qualified clinician.
06Beyond 12 weeks: Long-term safety data for unsupervised supplementation are limited; avoid assuming that ongoing use remains appropriate without periodic reassessment.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Pregnenolone is a steroid-hormone precursor, not an inert vitamin; downstream conversion can differ widely between people.
Possible adverse effects include insomnia, agitation, headache, gastrointestinal upset, acne, oily skin, hair changes, and altered libido.
Use only with clinician guidance if pregnant, trying to conceive, breastfeeding, or using hormonal contraception or hormone replacement therapy.
Avoid unsupervised use with a history of hormone-sensitive cancer, endometriosis, uterine fibroids, polycystic ovary syndrome, or unexplained vaginal bleeding.
People with bipolar disorder, psychosis, severe anxiety, or seizure disorders should discuss use with their treating clinician before starting.
Seek Medical Attention If:
You develop mania, hypomania, hallucinations, severe agitation, suicidal thoughts, or a marked worsening of psychiatric symptoms.
You experience chest pain, fainting, severe shortness of breath, facial swelling, or signs of a serious allergic reaction.
You develop heavy or unexplained vaginal bleeding, severe pelvic pain, breast changes, or rapid virilizing symptoms.
Persistent insomnia, severe headache, or mood changes occur after starting or increasing the dose.
Quality Indicators
Verified Marker
Lot-specific certificate of analysis
Choose products providing a batch-specific COA that identifies pregnenolone, reports assay results, and matches the lot number printed on the bottle.
Verified Marker
Independent identity and purity testing
Prefer manufacturers that disclose third-party HPLC or comparable chromatographic testing for identity and purity rather than relying only on in-house claims.
Verified Marker
Heavy-metal and microbiological screening
A stronger quality file includes current testing for heavy metals and microbial contaminants, particularly for encapsulated powder products.
Acceptable Range
Clear capsule strength and excipient disclosure
The label should state milligrams per capsule, serving size, all inactive ingredients, storage instructions, manufacturer contact details, and an expiration date.
Quality Concern
Unverifiable testing or exaggerated claims
Avoid products with no lot-specific documentation, implausible hormone-balancing or anti-aging promises, proprietary blends obscuring dose, or inconsistent capsule labeling.
Research Citations
- Pregnenolone treatment in schizophrenia: a double-blind, placebo-controlled trial
Ritsner, M. S., Bawakny, H., Kreinin, A., et al., 2010, Journal of Clinical Psychiatry - Pregnenolone treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial
Mayo, L. M., et al., 2014, Neuropsychopharmacology - A randomized controlled trial of pregnenolone and symptom reduction in veterans with chronic posttraumatic stress disorder
Rasmusson, A. M., Marx, C. E., Jain, S., et al., 2016, JAMA Psychiatry - Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence
Marx, C. E., Bradford, D. W., Hamer, R. M., et al., 2011, Neuroscience - Neurosteroids: a novel function in the brain
Vallée, M., Mayo, W., Le Moal, M., 2001, Brain Research Reviews
Research Focus
neurosteroid, master steroid precursor, memory, cognitive enhancement, mood, GABA modulation, NMDA, neuroprotection, schizophrenia, PTSD, adrenal health, cholesterol conversion
Frequently Asked Questions
What should researchers watch for with Pregnenolone?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Pregnenolone?
Days 1–7 (reported in cited studies): some individuals report changes in sleep, energy, dream vividness, mood, or gastrointestinal comfort; others notice no immediate subjective effect.
How is Pregnenolone typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →